Wound ~ re-epithelialization
TB-500 Tissue Repair Research: Wound Healing and Re-Epithelialization Findings
The wound-healing record is the strongest thread in this literature — and it is almost entirely on full-length thymosin beta-4. Here are the numbers, with the molecule each was measured on.
What the wound-healing data show
TB-500 tissue repair research is, at its core, thymosin beta-4 wound-healing research. The defining result: in a rat full-thickness wound model, topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at four days and up to 61% at seven days versus saline, increased wound contraction (≥11% by day 7), and raised collagen deposition and angiogenesis; as little as ~10 pg stimulated keratinocyte migration two- to three-fold [3].
Those are the largest, cleanest tissue-repair numbers in the record — and they are on the ~4963 Da parent protein, not the ~889 Da heptapeptide sold as TB-500 [3]. The consolidating review explains why the protein works in wounds: it binds actin and mobilizes cells, decreases myofibroblast number to reduce scar formation, is released by platelets and macrophages after injury to limit apoptosis and inflammation, and promotes angiogenesis — the rationale that took thymosin beta-4 into clinical trials for dermal wounds [5]. Whether the fragment reproduces any of this in humans is unproven; no completed controlled trial of the seven-mer exists [5].
What is TB-500 used for in research?
In animal and topical-human models, thymosin beta-4 — the parent protein of the TB-500 fragment — is studied for tissue repair, wound healing, muscle and ligament recovery, cardiac and neurological repair, and angiogenesis [5]. The breadth comes from a single upstream mechanism: actin binding and the cell migration it regulates [1]. Efficacy of the isolated heptapeptide in humans is unproven, with no completed controlled trial of the fragment for any indication [5].
Does TB-500 help wound healing?
Full-length thymosin beta-4 accelerated wound healing in animal models, increasing re-epithelialization, contraction, collagen deposition, and angiogenesis [3]. A dermal-healing review summarizes the protein's promotion of skin wound repair across models [7], and thymosin beta-4 improved dermal burn-wound healing via downregulation of the receptor for advanced glycation end-products in diabetic (db/db) mice [9]. The fragment's wound-healing efficacy in humans has not been demonstrated in controlled trials [5].
Does TB-500 help corneal or eye healing?
Topical thymosin beta-4 — formulated clinically as RGN-259 — accelerated corneal re-epithelialization in animals and improved dry-eye signs and symptoms in randomized human trials [5]. This is the one area with controlled human evidence, and it is full-length Tβ4 delivered topically to the ocular surface, not the TB-500 heptapeptide given systemically [5]. The corneal record is the clearest demonstration that the protein does what the mechanism predicts; it does not transfer to the fragment by assumption.
How long does it take for TB-500 to work for injury healing?
No controlled human timeline exists [5]. The available timeline is from the rat full-thickness wound model, where topical or intraperitoneal thymosin beta-4 raised re-epithelialization by 42% at four days and up to 61% at seven days versus saline [3]. That is an animal timeline on the parent protein; human timelines for the fragment are not established, and community "loading then maintenance" schedules have no published clinical validation [5].
How thymosin beta-4 closes a wound, step by step
The wound-repair effect is not a single action but a sequence the protein drives at several points. First, migration: even picogram amounts of thymosin beta-4 stimulate keratinocyte migration, and the protein mobilizes endothelial cells and progenitors toward the wound bed [3]. Second, matrix remodeling: thymosin beta-4 promotes matrix metalloproteinase expression during wound repair, the enzymatic step that lets cells advance through and reorganize the extracellular matrix [8]. Third, vascularization: it promotes angiogenesis, building the new vessels a healing wound needs [3].
Fourth, and central to the anti-scarring story, the protein decreases myofibroblast number — the contractile cells that drive fibrosis — which lowers scar formation while still allowing contraction and collagen deposition [5]. Fifth, it limits the early damage: released by platelets and macrophages at the injury site, thymosin beta-4 reduces apoptosis and inflammation and limits microbial growth [5]. The consolidating review assembles these into the rationale that carried the protein into clinical trials for dermal wounds, corneal injury, and heart and CNS repair [5]. Every step in that sequence was characterized on the full-length protein; the fragment's contribution at research doses is not separately established [5].
The recent wound-repair literature, 2024-2025
The wound-repair thread has continued. A 2025 comparative study found that combined thymosin beta-4 and selenium improved diabetic-ulcer healing, supporting the wound-repair angle in metabolically impaired models [12]. A 2025 biomaterials study showed that a thymosin beta-4-exosome-loaded hemostatic and antibacterial hydrogel improved vascularized wound repair, illustrating engineered delivery approaches to the protein [14]. And a 2024 study reported that thymosin beta-4 improved the survival of cutaneous flaps in rats and activated Wnt/β-catenin signaling, supporting tissue-survival and angiogenesis mechanisms in reconstructive contexts [15]. Each used the protein or a protein-loaded system, not the bare heptapeptide.
What the wound record does and does not support
Read together, the wound literature supports a clear statement and refuses an overreach. It supports this: full-length thymosin beta-4 reproducibly accelerates wound repair in animal models and in topical-ocular human trials, through actin-driven cell migration, angiogenesis, and reduced scarring [3][5][7]. It does not support the claim that the Ac-LKKTETQ heptapeptide marketed as TB-500, given by injection at research-community doses, produces those outcomes in people — there is no completed controlled trial of the fragment for any indication [5].
The diabetic-ulcer and burn findings tighten this further: even the impaired-healing models that look most like a clinical target used the protein or a protein-loaded delivery system, not the bare seven-mer [12][9]. The most accurate summary of TB-500 tissue repair research is that the parent protein has a genuine, sourced wound-healing record, and the fragment inherits the hypothesis, not the evidence. For the regulatory picture on access, see TB-500 legal status.